Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat
November 12, 2020 8:03 AM ESTHarmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $45.6 million versus the consensus estimate of $40.07 million.
Third Quarter 2020 Financial Highlights:
Net product revenue was $45.6 million for the third quarter ended September 30, 2020.Research and development expenses were $4.2 million for the third quarter of 2020 compared with $4.3 million for the third quarter of 2019.Sales and marketing expenses were $12.6 million for the third quarter of 2020 compared with $12.9 million for the third... More